Management

Position: CEO and President since 2021. Employed since 2021.

Education: BSc in business administration and economics from Örebro University.

Experience: Former experience in the pharmaceutical industry includes CEO at Sedana Medical Group (2017-2021) and CEO at Unimedic Group (2010-2016), CEO at Eisai AB (2005-2010) and additional 10 years of experience in leading positions in sales and marketing at AstraZeneca (including launch of Nexium), Meda and Wyeth.

Other current assignments: Member of the Board of FrostPharma AB, FrostPharma Holding AB, PMD Device Solutions AB and PMD Device Solutions Sweden AB. Deputy CEO and deputy Member of the Board of Waxholm by the sea AB.

Holdings in Cinclus Pharma: Ordinary shares: 104,400 (own), Share rights (PSP2024): min 11,600 max 104,400, ESOP 24/27: 200,000, QESO: 22/25: 700 (conv. Term 1:80), QESO: 24/27: 7,391.

Position: CEO between 2014-2021, CSO since 2021. Employed since 2014.

Education: BSc University of Gothenburg, Ph.D in Pharmacology from Lund University.

Experience: 30 years’ of experience from Astra/AstraZeneca. Preclinical project leader for Losec, the first PPI (Proton Pump Inhibitor) on the market. Preclinical project leader for Nexium including clinical, marketing and regulatory support. Discovery project leader on the P-CAB (Potassium-Competitive Acid Blocker) programme that brought linaprazan through the phase II clinical studies.

Other current assignments: Member of the Board of OBX Invest AB.

Holdings in Cinclus Pharma: Ordinary shares: 1,908,000 (via related party), Share rights (PSP2024): min 3,325 max 16,625.

Position: CFO since 2021. Employed since 2021.

Education: BSc in Business Administration and Economics from Stockholm University.

Experience: Former CFO of Sedana Medical Group (2017-2021) and Managing Director at Cross Pharma AB (2015-2016). Maria has also extensive experience from leading positions within finance for the past 25 years within Medivir, Biovitrum, Bristol Myers Squibb and Ericsson.

Other current assignments: Member of the Board of FAYSIT – Finance At Your Service In Tyresö AB.

Holdings in Cinclus Pharma: Ordinary shares: 11,400 (own and via related parties), Share rights (PSP2024): min 5,375 max 26,875, QESO: 22/25: 700 (conv. term 1:80), QESO: 24/27: 7,391, Warrants 21/24: 1,450 (conv. term 1:80).

Position: COO since 2021. Employed since 2021.

Education: Ph.D in Cell- and Molecular Biology from Lund University.

Experience: Former experience in the pharmaceutical industry includes CEO, COO and Clinical Advisor at SDS Life Science (2017-2021), Project manager RWE/register-projects, QRC-Stockholm, (2012-2015), Global- and Clinical Project Manager and Preclinical Scientist in different positions at AstraZeneca R&D (2001-2012). More than 20 years of experience from drug development and project management.

Holdings in Cinclus Pharma: Ordinary shares: 1 000 (own), Share rights (PSP2024): min 1,000 max 4,000, QESO: 22/25: 700 (conv. term 1:80), QESO: 24/27: 7,391, Warrants 21/24: 1,450 (conv. term 1:80).

Position: CMO since 2022. Employed since 2022.

Education: MD and Ph.D in Medical Sciences from Karolinska Institutet.

Experience: Consultant in internal medicine and hematology/hematooncology with more than 15 years’ of clinical experience. From 2009 full time in the pharmaceutical industry at different positions within medical affairs and clinical development at national, regional and global levels in Genzyme, Roche, Alexion, Alnylam and Oncopeptides.

Holdings in Cinclus Pharma: Ordinary shares: 3 325 (own), Share rights (PSP2024): min 3,325 max 16,625, QESO: 22/25: 700 (conv. term 1:80), QESO: 24/27: 7,391, Warrants 21/24: 1,450 (conv. term 1:80).

Position: Commercial Director since 2022, consultant since 2022.

Education: BSc, Biochemistry, Molecular Biology, Microbiology from Sydney University and Master Commerce, Marketing and Finance from University of NSW.

Experience: Extensive experience from the pharmaceutical industry. Former Head of Digital Transformation at Novartis and Ass. Global Brand Director of Diabetes at Novartis. Several executive positions within AstraZeneca such as VP Nexium, Global Marketing and Development, Global Product Director and Marketing Director Gastroenterology for Nexium and Losec.

Other current assignments: Member of the Board of PCW Consulting AB. Deputy Member of the Board of Wallich Composite AB and Wallich Holding AB.

Holdings in Cinclus Pharma: -

Position: Head of CMC and IP since 2024. Employed since 2022.

Education: MSc in Chemical Engineering and Ph.D. in Polymer Technology from Royal Institute of Technology.

Experience: Bengt has more than 25 years experience from the pharmaceutical industry at companies such as AstraZeneca, Recipharm, etc. He has a broad experience from roles with responsibilities within analytical and product development, project management, and quality assurance. Bengt has also worked as CMC consultant.

Holdings in Cinclus Pharma: Ordinary shares: 3 325 (own), Share rights (PSP2024): min 3,325 max 16,625, QESO: 22/25: 350 (conv. term 1:80), QESO: 24/27: 7,391.

Position: Head of Regulatory Affairs since 2024. Employed since 2022.

Education: MSc in Pharmacy from Uppsala University.

Experience: Former experience include Consultant and Regulatory Advisor at SDS Life Science (2019-2022). Assessor at the Swedish Medical Products Agency Department of Efficacy and Safety (2007-2019), Departmeent of Regulatory Affairs (2003-2007). More than 20 years of experience in Regulatory Affairs and Drug Development.

Holdings in Cinclus Pharma: Ordinary shares: 1 490 (own), Share rights (PSP2024): min 1,490 max 5,960, QESO: 22/25: 350 (conv. term 1:80), QESO: 24/27: 7,391.